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Introduction
Transcatheter pulmonary valve replacement (TPVR) with the Melody valve was first performed by Bonhoeffer et al. in 2000, 1 and was introduced in the US in 2007 through a prospective, multicenter Investigational Device Exemption (IDE) trial. [2] [3] [4] A number of single and multicenter reports have confirmed that TPVR is technically reproducible and results in excellent acute and short-term outcomes, with reduction of right ventricular outflow tract (RVOT) obstruction, elimination of pulmonary regurgitation (PR), and clinical improvement. [2] [3] [4] [5] [6] [7] [8] [9] At a functional level, TPVR is followed by improved circulatory efficiency and ventricular strain, enhanced cardiopulmonary exercise function in some patients, and better quality of life. [10] [11] [12] [13] [14] [15] [16] [17] [18] Although these and other reports helped substantiate TPVR as a valuable tool in the management of patients with postoperative RVOT dysfunction, the lack of longer-term follow-up data remains an important limitation in the Melody valve literature. To date, the studies with the longest follow-up were a 2008 report of 155 patients from Bonhoeffer's group, and a 63-patient series collected through an Italian registry that was published in 2013, which reported outcomes a median of 2.3 and 2.5 years post-TPVR, respectively. 5, 6 To address this deficiency, we analyzed mid-term hemodynamic and clinical outcomes in the IDE trial patients, who were all at least 4 years out from Melody valve implant.
Methods

Patients and Study Protocol
The US Melody valve IDE trial was a non-randomized, prospective study sponsored by Medtronic, Inc. (Minneapolis, MN) that enrolled patients at 5 sites. The study was conducted under IDE# G050186 and was registered in ClinicalTrials.gov (Identifier: NCT00740870). The hese and other reports helped substantiate TPVR as a valuable tool in the manag gem em emen en ent t t of of of patients with postoperative RVOT dysfunction, the lack of longer-term follow-up data remains an imp mp mpor or orta ta tant nt nt lim m mit it itat a a ion in the Melody valve litera ra ratu tu tur re. To date, the studi di die e es with the longest fo fo foll l lo ow-up were e e a a a 2 200 00 08 8 year ar ars s s po po post st st T T -TPV PV PVR R R, r r res es espe pe pect ct ctiv i ivel el ely. 5,6 5,6 , To To To a a add dd ddre re ress ss ss t t thi hi his s s de de defi fi fici ci cien en ency c cy, we e we a a ana na naly l lyze e zed d d d protocol was approved by the Food and Drug Administration, and by the Institutional Review
Board at each institution. The trial was initially designed to follow patients for 5 years after implant, or until explant, but was modified in 2011 to allow follow-up out to 10 years in patients who provided supplemental written informed consent. The trial design, protocols, and procedural and short-term results were described previously. [2] [3] [4] 14, 15 
Follow-up Evaluation
Follow-up consisting of echocardiography, cardiopulmonary exercise testing, chest radiography, and a clinical history and exam were conducted annually, within pre-determined windows, at the implanting center, or elsewhere after 5 years if more convenient for the patient. Details of follow-up evaluation protocols were summarized previously. [2] [3] [4] 14, 15 Radiographic studies were performed to assess for Melody valve stent fractures (MSF), which were classified according to a previously reported system 19 ; stent fracture assessment did not include examination of conduit stents (i.e., pre-stents) placed at a prior procedure (existing) or during the TPVR procedure (new). The protocol for coronary artery compression testing was discussed in detail in a prior report. 20 Endocarditis was defined and reported as described in a prior report. 21 All data, including findings on non-protocol evaluations, reinterventions, and adverse events were recorded on pre-specified case report forms and entered into the web-based data collection system maintained by the sponsor. The database was locked for this analysis on May 16, 2014.
Statistical Analysis
Procedural results were described previously, but, given the reported relationships between residual obstruction and adverse outcomes, 4, 18, 21, 22 a new analysis was conducted of factors associated with a higher early post-implant gradient, which included all patients in whom TPVR was attempted. Follow-up analyses only included patients discharged with a Melody valve in follow-up evaluation protocols were summarized previously. [2] [3] [4] 14, 15 Radiographic ic c s s stu tu tudi di dies es es w w wer er ere e e performed to assess for Melody valve stent fractures (MSF), which were classified according to a prev v vio io ious us usly ly ly r r rep ep e or r rte te ted d d system 19 ; stent fracture asses es ssm sm sment did not include ex ex xamination of conduit t t ten n nts (i.e., pre--st st sten nts ts s) ) ) pl pl plac ac aced ed ed a a at t t a a pr pr prio ior r r p proc ce ced du d re (e e exis s sti ti ting ng ng) ) ) o o or d d dur ur uri in ing g g th th the e TP P PVR VR VR p p pro ro roce e ed du dure re re n n new ew ew). ). ) The p p pr ro r to o oco o ol fo o or coro o ona na nary ry ry a a art rt rter ry y y c co c m m mpr r ressio io on te te es st stin ng g g wa wa was s d di disc sc cus s sse ed in in in d d detai i il i i in a a p p prior r r e e epo po port rt rt. 20 20 En En Endo do doca ca card rd rdit it itis is is was as as d d def ef efin in ined ed ed a a and nd nd r r rep ep epor or orte te ted d d as as as d d des es escr cr crib ib ibed ed ed i i in n n a a a pr pr prio io ior r r re re repo po port rt rt. 21 21 Al Al All l l da da data ta ta, between groups using chi-square analysis or Fisher's exact test. Exploratory multiple linear regression analysis was performed to evaluate factors associated with a higher post-TPVR RVOT gradient. Data were presented as median (minimum-maximum) or frequency (%). The authors had full access to and take full responsibility for the integrity of the data. All authors read and agreed to the manuscript as written.
Results
Patients and Procedural Outcomes
The US IDE trial enrolled 171 patients with postoperative right ventricular outflow tract (RVOT) conduit dysfunction from January 2007 through January 2010. Of these, 167 underwent catheterization, and 150 had a Melody valve implanted (Figure 1) , which was deployed in the intended location in all cases. The cohort was almost evenly divided between pediatric patients (age 18 years) and adults, and there were several notable diagnostic differences between these populations ( Table 1) .
As described previously, 2,3 1 patient had emergent pulmonary valve replacement for conduit rupture after TPVR and 1 died of cerebral hemorrhage after a course complicated by coronary artery dissection before Melody valve implant and subsequent mechanical circulatory support. The remaining 148 patients were discharged with the valve in place and constitute the study cohort.
Acute Hemodynamic Results
TPVR provided a competent pulmonary valve in all patients: on the discharge echocardiogram, PR was absent or trivial in 140 patients and mild in 5 (valve not visualized in 3), which was a significant improvement from pre-implant, when 79% of patients had moderate (n=45) or severe conduit dysfunction from January 2007 through January 2010. Of these, 167 und der er erwe we went nt nt catheterization, and 150 had a Melody valve implanted (Figure 1) , which was deployed in the ntend nd nded ed ed l l loc oc ocat a a ion n n in in i all cases. The cohort was alm lm mos os ost evenly divided bet et etw w ween pediatric patients a a age e e 18 years) ) ) an an a d ad ad adul ul ults ts ts, , , an an nd d d th th ther er re e e we w were s s sev ev veral l n n notab ab able le le d d dia ia iagn gnos os osti ti tic c di di diff feren en nce ce ces s be be betw tw twee ee een n n th th thes es ese e e po o opu pu pula l l tions s ( ( (Ta T T b bl b e e e 1) ).
As As As d d des es escr cr crib ib ibed ed ed p p pre re revi i viou o ousl sl sly, 2,3 2,3 , 1 1 1 p p pat at atie ie ient nt nt h h had ad ad e e eme me merg rg rgen en ent t t pu p pulm lm lmon on onar ar ary va a valv l lve e e re re repl pl plac ac acem em emen en ent t t fo fo for r r (n=69) PR and 9% (n=14) had trivial or no PR (p<0.001). TPVR was also followed by a significant reduction in the mean Doppler RVOT gradient, from a median of 33mmHg (5-97mmHg) to 17mmHg (3-51mmHg) on the discharge echocardiogram (p<0.001). However, a subset of patients had discharge gradients >20mmHg (n=49, 33%) or >25mmHg (n=17, 12%).
Diagnostic and procedural factors associated with a higher discharge gradient are summarized in Table 2 . On multivariable linear regression, a pre-implant mean RVOT gradient >35mmHg and absence of a new pre-stent were associated with higher discharge gradient, but provided only modest explanatory power (model R 2 =0.08, p<0.001). In general, pediatric patients had higher gradients both before and early after Melody valve implant than adults. locked, all patients were at least 4 years out from TPVR. However, complete follow-up was not available in some patients, most of whom were not local to the implanting center and had missed the prior protocol evaluation, but were known to be alive and in care with another physician. If such patients had indicated an intention to continue in the protocol, they were not classified as lost to follow-up, and were analyzed only through the most recent protocol testing.
Follow-up
RVOT Reintervention
In addition to the patient who suffered an acute conduit rupture, 32 patients underwent patients, TPV-in-TPV in 19, and TPV explant in 7 (Figure 1 , Table 3 ). Three other patients had a bare stent placed in the RVOT conduit proximal or distal to the TPV for stenoses that were recurrent or not fully treated at the TPV implant procedure; in all 3 cases, the TPV was well functioning and not affected by the reintervention. Details of and indications for reinterventions are summarized in Table 3 . Freedom from reintervention on the Melody valve was 76±4% at 5 years, and on multivariable Cox regression was shorter in patients with a homograft conduit, a conduit that was not pre-stented, a discharge RVOT mean Doppler gradient >25mmHg, and preimplant moderate/severe TR ( Table 4 ).
There were several notable interactions between conduit stenting and pre-and post- 
Transcatheter Melody Valve Reintervention
Twenty-five patients underwent transcatheter TPV reintervention, only 3 of whom had a new pre-stent placed before the original Melody valve implant. In 6 of these patients, the initial , p p p=0 0 0.00 00 002) 2) 2). Pa Pa Pati ti tien en ents ts ts wit it ith h h no no no n n new e ew p p pr r re e e-st st sten en ent t t, a a a p p pre re re i i -imp mp mpla la lant nt nt g g gra ra radi di dien en en n reintervention was redilation of the Melody valve. Five of these patients had the valve implanted on the smallest size (18mm) delivery system, 14 were among the first 50 implants overall and the first 10 at a given center, and all had relatively high residual gradients early after TPVR, with a mean Doppler gradient on the discharge echocardiogram >20 mmHg in all but 1. A MSF was diagnosed before the redilation in only 2 of these 6 patients.
The initial reintervention was a TPV-in-TPV implant in 19 patients. Including 1 other patient whose first reintervention was TPV dilation, 20 patients ultimately underwent implantation of a second Melody valve for TPV dysfunction, which consisted of RVOT obstruction associated with MSF in all cases. All patients who underwent TPV-in-TPV implant had 1 (n=1) or more (2 in 14, 3 in 5) pre-stents placed prior to implantation of the second Melody valve. After the second TPVR, the mean Doppler gradient fell in all patients, from 40mmHg (20-72mmHg) to 17mmHg (8-37mmHg) (p<0.001).
Eight of the 25 patients whose initial RVOT reintervention was redilation (3 of 6) or TPV-in-TPV implant (4 of 19) underwent another intervention during the study period, as detailed in Figure 1 and summarized in Table 3 . Freedom from a second reintervention after transcatheter reintervention (dilation or a second TPVR) was 70±11% at 3 years, and was significantly shorter if the first reintervention was redilation rather than TPV-in-TPV (p=0.048) ( Figure 2) . Freedom from subsequent RVOT reintervention after TPV-in-TPV (either as an initial reintervention or after prior Melody valve dilation) was 87±9% at 3 years after the second Melody valve was implanted (Figure 2) .
Melody Valve Explant
A total of 11 patients underwent Melody valve explant during follow-up, including the 7 whose initial reintervention was Melody valve explant and 4 who had the valve explanted after prior had 1 (n=1) or more (2 in 14, 3 in 5) pre-stents placed prior to implantation of the e e s s sec ec econ on ond d d Me Me Melo lo lody valve. After the second TPVR, the mean Doppler gradient fell in all patients, from 40mmHg (20-72mm mm mmHg Hg Hg) ) ) to to to 17m m mmH m m g (8-37mmHg) (p<0.001).
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Other Reinterventions
Reinterventions during follow-up that did not involve the RVOT are listed in Supplemental   Table 1 .
Melody Valve Stent Fracture
A MSF was diagnosed in 50 patients and a type II MSF was diagnosed in 25 (Supplemental Figure 1 ). At 5 years, freedom from any MSF was 61±5% and from a type II MSF was 83±3%.
Freedom from a type II MSF after the first MSF diagnosis was 50±8% at 3 years (Figure 3 ). Of 7 patients who were diagnosed with a type II MSF 2 or more years after the initial MSF diagnosis, most (n=5) did not have a pre-stent placed, and all had mean Doppler gradients at discharge <25mmHg.
Freedom from reintervention after diagnosis of a stent fracture was 51±8% at 3 years (Figure 3) , and by multivariable Cox regression was shorter in patients with a higher discharge RVOT TPV-in-TPV implants, 1 dilation, and 1 dilation followed shortly by explant) (Figure 4) . One patient developed endocarditis for the first time 16 months after RVOT reintervention, and another had a second episode 2.7 years after TPV-in-TPV implant.
Melody Valve Function
Among the 113 patients who were alive and free from reintervention, a median of 4 
Functional and Cardiopulmonary Status
Prior to TPVR, 14% of patients were in NYHA class I and 17% were in class III or IV. At every post-implant annual evaluation, at least 74% of patients were in class I and most others were in class II, with no more than 1-2% in class III or IV ( Supplemental Table 2 .
Cardiopulmonary exercise testing and spirometry data at baseline are summarized in years. In the overall population, however, there were no significant changes in the percent of predicted peak oxygen consumption (percent V O2 max). As reported previously, 14 the ratio of minute ventilation to carbon dioxide production at the anaerobic threshold (V E /V CO2 ) improved early after TPVR and remained stable thereafter throughout follow-up (median 28-29 at all follow-up evaluations, p 0.001). Other than comparison of exercise measures according to age ( (15 15 15 the median V O2 max was 34% of predicted (21-73%). Baseline respiratory abnormalities were not associated with changes in percent V O2 max after TPVR, but there was greater improvement in maximum work among patients with a normal FEV 1 and/or FVC compared to those in whom both were abnormal (p<0.03).
Changes in Practice and Outcome Over Time
There were several changes in practice over the course of the IDE trial. Conduit pre-stenting was not permitted during the first 35 implants, after which the protocol was modified to allow concomitant procedures. Accordingly, placement of a new pre-stent was less common in the first 50-patient tertile than the second or third (10% vs 54% and 42%; p<0.001). Overall, only 36% of patients underwent pre-stenting (Figure 1) . In addition, there were changes in implant practice that were not associated with protocol modifications. For example, 32% of patients in the first tertile underwent TPVR with the largest size 22 mm delivery system, but this increased to 56% during the second tertile and 84% during the third (all p 0.008), whereas use of the smallest 18 mm system fell from 36% to 6% to 4% (the nominal conduit diameter was 1.5 mm smaller in first tertile patients than those treated later [p<0.001]). In contrast, post-implant dilation of the Melody valve was more common in the first 50 patients (66%) than the second (38%) or third (36%) (p=0.004).
There were also differences in outcomes between the first and second 50 patients, Figure 2 , 5-year freedom from Melody valve reintervention was 68±7% in first-tertile patients, compared with 87±5% in the second tertile patients underwent pre-stenting (Figure 1) . In addition, there were changes in imp mp mpla la lant nt nt p p pra ra ract ct ctic ic ice e e hat were not associated with protocol modifications. For example, 32% of patients in the first ertil il le e e un un unde de derw rw rwen nt t t TP T T VR with the largest size 22 mm mm mm delivery system, bu bu but t t this increased to 56% d du duri ri ring the secon on ond d te ert rt rti i ile e e an an and d d 84 84 84% % % du du duri ri ring g n the he he t t th hird d (a all p p p 0 0 0.00 00 008) ) ), wh wh wher er erea ea eas s use e e of of of t t the he he s sma ma mall l les es est t t 18 evidenced by frequent abnormalities of FEV 1 and FVC in this cohort, and proposed by others. 23 Notably, patients with normal spirometry pre-TPVR experienced greater improvement in peak work after implant. Also, as NYHA class tends to reflect perceptions of limitation at submaximal exercise, this discrepancy may indicate a difference between experiential and peak-exercisederived cardiopulmonary limitations. This hypothesis is supported by the higher maximum work rate after TPVR in this series, and by the significant cardiac, exercise, and respiratory differences between patients in lower and higher NYHA classes. Prior studies found inconsistent physiologic effects of TPVR, with improved exercise function in patients with RVOT obstruction as an indication for implant, but not in those with primary PR. 10, 11, 16 Although the current study did not examine exercise function in depth, the long-term relationship between post-TPVR changes in hemodynamics, symptomatic status, and exercise physiology deserves further detailed analysis.
Stent Fracture, RVOT Obstruction, and Melody Valve Reintervention
Another notable finding of this study was the ongoing risk beyond 4 years post-TPVR of MSF and associated RVOT obstruction. With the additional follow-up duration and greater number of outcome events than prior studies, this analysis also provided more robust estimates of progression of MSF from minor to major, and of freedom from RVOT reintervention after diagnosis of a MSF. These observations provide further support for the previously advanced argument that a MSF per se is not necessarily a critical adverse outcome; rather, the relevant outcome is recurrent RVOT obstruction that results from loss of TPV integrity, which is not the inevitable outcome of a MSF.
The most common indication for reintervention after TPVR was MSF with recurrent RVOT obstruction, interrelated outcomes that prior studies have shown to be associated with a constellation of factors. 4, 19 In an effort to understand better the interaction between TPV examine exercise function in depth, the long-term relationship between post-TPV V VR R R ch ch chan an ange ge ges s s in in in hemodynamics, symptomatic status, and exercise physiology deserves further detailed analysis. RVOT gradients. In that analysis, pre-stenting was associated with a low risk for reintervention regardless of pre-or post-implant gradient (too few pre-stented patients underwent reintervention to determine the importance of residual gradient), but so was the combination of low pre-implant and discharge gradients regardless of pre-stent status. Patients at highest risk for reintervention were those who did not receive a pre-stent and had high RVOT gradients pre-implant and at discharge. This analysis indicates that pre-stenting is protective against reintervention, but also suggests that more thorough reduction of RVOT obstruction in patients with results in better long-term outcomes, and identifies patients with minor conduit obstruction as a subset in whom the benefits of pre-stenting are less clear.
Sten n nt t t Fr Fr Frac ac actu tu ture, RV R R OT Obstruction, and Melo o ody dy dy Valve Reintervent nt tio io ion
TPV implanters are often faced with the dilemma of how aggressively to treat RVOT stenosis, of whether to leave a mild residual gradient or expand the conduit further. We and others have argued that thorough gradient reduction is important for a combination of reasons. 4, 21, 24 The above analysis supports that contention in patients without a pre-stent, and we expect that it will apply in pre-stented patients as well, although there were too few reinterventions in that cohort to determine risk factors. This is a difficult question to address retrospectively, and is beset by one of the major challenges in studying TPV therapy, namely, heterogeneity of the target population and implant environment, and variability of the procedure itself. This diversity, in a small sample, makes it difficult to adjust adequately for potential confounders, while blanket evaluation of the full cohort may obscure important differences between subgroups. Accordingly, as TPVR therapy expands to younger and smaller patients, or those with dysfunction of a native or patched RVOT, 27, 28 ysis is is s s sup p uppo po port rt rts s s t t tha ha hat t t co co cont nt nten en enti ti tion on on i i in n n pa pa pati ti tien en ents ts ts wit it itho ho hout t ut a a a p p pre re re s s -ste te tent nt nt, an an and d d we we we e subgroup or interaction analyses will be critical if we are to achieve an incisive understanding of best practices for Melody valve therapy.
The aforementioned analysis was one attempt to drill down, and substantiated the benefit of thoroughly relieving RVOT obstruction independent from that of pre-stenting. As our understanding of the benefits of pre-stenting and risk factors for MSF improves, it is plausible that major MSF after TVPR will be nearly eliminated. Along these lines, it seems reasonable to propose that the patients in this trial who were not pre-stented and developed MSF with recurrent RVOT obstruction, then underwent TPV reintervention, may not be representative of current practice. To provide a more realistic, albeit hypothetical, estimate of the durability of a protected Melody valve, we simulated a scenario in which the problems of major MSF and consequent RVOT obstruction are overcome, by analyzing freedom from reintervention in patients who did not develop a type II MSF. In that speculative analysis, 5-year freedom from TPV reintervention was 91±3%, compared with 76±4% in the full cohort, and was shorter in patients with a higher discharge RVOT gradient. These observations are consistent with our previously advanced supposition about the importance of residual obstruction in pre-stented patients and support the recommendation for thorough relief of RVOT obstruction at the time of TPVR.
Other Adverse Melody Valve-Related Outcomes
Consistent with recent reports focused on the issue of endocarditis after TPVR, 21 who died) and a mitigating factor in 3 others. Thus, infection and endocarditis, which were explored in the IDE population in combination with 2 other prospective Melody valve trial cohorts in a prior report, 21 is clearly a high-priority issue for ongoing investigation and will continue to be a focal point in analyses of this technology. The role of Melody valve redilation for obstruction without associated MSF is less clear.
Outcomes of Transcatheter Melody Valve Reintervention
Redilation was performed in 7 patients, most of whom underwent TPVR early in the trial, had the valve implanted on the smallest delivery system, and had a relatively high discharge gradient, possibly indicating suboptimal initial therapy. There were too few patients to estimate freedom from further reintervention in this cohort, but 3 of the 7 underwent another reintervention within a year, suggesting that the benefits of redilation may be limited. Nevertheless, it is possible that isolated TPV redilation will be effective in some patients, such as those who undergo TPVR at a small size and develop RVOT obstruction due to somatic growth.
Learning Curve
There were several noteworthy changes in implant practices and outcomes over time, which likely reflected learning curve effects as well as protocol modifications and an evolving eintervention. The durability of the second valve in a protected environment, afte te er r r th th the e e fa fa fail il ilur ur ure e e of a first unprotected valve, supports the utility of pre-stenting and the general hemodynamic h h he e e va a valv l lve e e im im impl pl plan an ante te ted d d on on on t t the he he s s sma ma mall ll lles es est t t de de deli li live e very r ry s s sys s yst t tem em em, an an and d d ha ha had d d a a a re re rela la lati ti tive e vely l ly hi hi high gh gh d d dis is isch ch char ar arge ge ge g g gra ra radi di dien en ent t t t understanding of better practices. 3, 5, 19, 22 Patients implanted during the first third of the trial were less likely to have a new pre-stent placed, and more likely to undergo TPVR with the smallest delivery system (18mm) and to have the implanted Melody valve post-dilated. These differences corresponded to less complete relief of RVOT obstruction and shorter freedom from MSF and reintervention in the first 50 patients than those enrolled later. Because this series represents the first prospective multicenter trial, and the first experience with TPVR in the US, the results in the earliest patients, marked by a relatively high rate of MSF and consequent reintervention, reflect a naïve experience. Thus, although the data provide important insights, they are not representative of contemporary best practices, which include maximal relief of RVOT obstruction and, in most cases, implantation of one or more conduit pre-stents. Even once the trial protocol allowed prestenting, fewer than 50% of patients received a pre-stent, substantially less than in more recent series. 6, 7, 32 Accordingly, while these data will necessarily serve as a landmark, given that they represent the longest reported follow-up, the freedom-from-event analyses of this cohort almost certainly overestimate the risk of MSF, reintervention, and explant relative to contemporary practice.
Limitations
Although this study is unique and provides important new data, it nevertheless suffers from important limitations. The population was heterogeneous, and several procedural parameters were not strictly guided by the trial protocol, such as whether to pre-stent, how many or what type of stents to implant, and how aggressively to reduce the RVOT gradient before or after Melody valve implant. The latitude that these discretionary factors provided to the operator was clinically necessary, but potentially confounded the analysis of outcomes. Similarly, although there was general consensus among investigators about a reasonable threshold for reintervention cases, implantation of one or more conduit pre-stents. Even once the trial protocol ol ol a a all ll llow ow owed ed ed p p pre re retenting, fewer than 50% of patients received a pre-stent, substantially less than in more recent eries es es. 6,7 , , ,32 , , Ac A A co o ord rd rdingly, while these data will n nec ec eces essarily serve as a land nd ndmark, given that they (a mean Doppler RVOT gradient >35-40mmHg), criteria for and methods of reintervention were not specified by the protocol, and practices varied. The statistical analyses in this study were descriptive, with no pre-specified hypotheses, and therefore should be considered exploratory.
There were no multiple testing adjustments for controlling type I error. A number of patients (who typically lived elsewhere) did not attend the most recent prescribed protocol evaluation at the implanting center, although most indicated an intention to continue in the study; thus, the total available follow-up for this analysis was less than anticipated. This may have introduced limited bias, although it was known for most of these patients that no reintervention or serious adverse events had occurred (still, only data collected per protocol were included).
Conclusions
TPVR with the Melody valve continues to provide good hemodynamic and clinical results 4-7 years after implant. Primary valve failure was rare. The main cause of TPV dysfunction was stenosis related to MSF, which was less common once pre-stenting became more widely adopted, as other reports also demonstrated. 4, 6, 7, 32 Efforts to prevent or reduce hemodynamically important MSF are likely to yield even better long-term outcomes than documented in this series, and should be an ongoing focus. Similarly, endocarditis was an important adverse outcome during follow-up, and continued efforts to understand the pathophysiology of and risk factors for endocarditis after TPVR are warranted.
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Funding Sources: This study was sponsored by Medtronic, Inc. 20 6 had a conduit that was too large for Melody valve implant according to protocol criteria, 3 had conduit function that was better than expected or did not meet the protocol criteria for implant, 1 had an adequate hemodynamic result with angioplasty alone, and 1 had pulmonary artery rather than conduit obstruction and needed surgery on the left ventricular outflow tract. ‡ Does not depict 2 patients who underwent TPV dilation or a second TPV-in-TPV after an initial TPV-in-TPV implant. Abbreviations: As in Table 1 Supplemental Figure 1 . This flow diagram depicts the breakdown of patients who did and did not have a new pre-stent placed at the TPVR procedure, and who did and did not have a stent fracture diagnosed or undergo Melody valve reintervention during follow-up (FU). FU durations are from implant until most recent follow-up in the no stent fracture and no reintervention groups, from implant until the first diagnosis of a stent fracture in the stent fracture group, and from the diagnosis of a stent fracture until reintervention or most recent FU in the stent fracture subgroups.
Conclusions
